Director, FDA Oncology Center of Excellence
Appears in 1 story
Oversees the review process behind today's hearing
For decades, oncologists changed breast cancer drugs only after a scan showed the tumor growing back. On April 30, 2026, an FDA advisory panel weighed a different approach: switch the drug the moment a blood test detects the resistance mutation — weeks or months before the cancer becomes visible on imaging.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
